Azitra (NYSEAMERICAN:AZTR – Get Free Report) posted its earnings results on Wednesday. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.05), FiscalAI reports.
Azitra Stock Performance
NYSEAMERICAN AZTR remained flat at $0.14 on Thursday. The company had a trading volume of 452,751 shares, compared to its average volume of 9,958,622. The business has a 50-day moving average price of $0.16 and a two-hundred day moving average price of $0.20. Azitra has a twelve month low of $0.10 and a twelve month high of $1.40.
Azitra Company Profile
Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.
The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.
Recommended Stories
- Five stocks we like better than Azitra
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
- Lumentum Just Delivered the AI Growth Investors Wanted
- Ryman Checks Into a $1.38B Hospitality Upgrade
Receive News & Ratings for Azitra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azitra and related companies with MarketBeat.com's FREE daily email newsletter.
